POST DETAILS

Post No: 634925 November 26, 2017, 02:39PM
Guest wrote: 1 Reply

CALGARY and SAN DIEGO, CA, Nov. 16, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced that it has entered into a Regional Licensing Agreement (The Agreement) with Adlai Nortye (Adlai), a biopharmaceutical company focused on discovering and developing important new treatments for cancer and metabolic diseases. Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.



https://www.prnewswire.com/news-releases/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd-866-million-regional-licensing-agreement-for-reolysin-658070813.html

Type the characters that you see in the box (5 characters).